This EVERSANA white paper explains the advantages of coordinating pharmaceutical product launches across the United States and Canada rather than launching sequentially. It argues that a synchronized North American strategy can maximize revenue, accelerate patient access, extend market exclusivity, and reduce commercialization costs through shared regulatory, medical, marketing, and operational resources. The paper addresses common misconceptions about Canadian pricing, reimbursement, and cross-border pricing impacts while highlighting opportunities for regulatory alignment, faster approvals, and patent extensions. It concludes that an integrated commercialization approach enables pharmaceutical companies to streamline launches, improve efficiency, support future global expansion, and maxi

Join for free to read